Anxiety and depression in COPD

Clinical Management of Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2002, Pages 549-582

  Eiser, Noemi ^a  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2342426789     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (199)

1. Angst J. Epidemiology of depression. Psychopharmacology 1992; 106:S71–S74
2. Sheik JI. Anxiety disorders and their treatment. Clin Geriatr Med 1992; 8:411–427.
3. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
4. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
5. House A. Mood disorders in the physically ill—problems of definition and measurement. J Psychosom Res 1988; 32:345–353.
6. Creed F. Assessing depression in the context of physical disease. In: Robertson MM, Katona CLE, eds. Depression and Physical Disease. Chichester, England: John Wiley and Sons. 1997.
7. Wells KB, Golding JM, Burnam MA. Chronic medical conditions in a sample of the general population with anxiety, affective and substance abuse disorders. Am J Psychiatry 1989; 46:1440–1446.
8. Moffic HS, Paykel ES. Depression in medical in-patients. Br J Psychiatry 1975; 126: 346–353.
9. Gift AG, McCrone SH. Depression in patients with COPD. Heart Lung 1993; 22:289–297.
10. Zigmond AS, Snaith RP. The Hospital Anxiety-Depression Scale. Acta Psychiatr Scand 1983; 67:361–370.
11. Lewis G, Wesseley S. Comparison of the General Health Questionnaire and the Hospital Anxiety and Depression Scale. Br J Psychiatry 1990; 157:860–864.
12. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9:139–145.
13. Johnson G, Burvill PW, Anderson CS et al. Screening instruments for depression and anxiety following stroke. Acta Psychiatr Scand 1995; 91:252–257.
14. Katon W, Schulberg H. Epidemiology of depression. Gen Hosp Psychiatry 1992; 14: 237–247.
15. Rodin G, Voshart K. Depression in the medically ill: an overview. Am J Psychiatry 1986; 143:696–705.
16. Clarke DC, Cavanaugh SVA, Gibbons RD. The core symptoms of depression in medical and psychiatric patients. J Nerv Ment Dis 1983; 171:705–713.
17. Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53:2243–2249.
18. Rodin G, Craven J, Littlefield C. Depression. In: The Medically Ill—an Integrated Approach. New York: Brunner/Mazel, 1991.
19. Feldman E, Mayou R, Hawton K, Ardern M, Smith EBO. Psychiatric disorder in medical inpatients. Q J Med 1987; 63:405–412.
20. Rapp SR, Vrana S. Substituting non-somatic for somatic symptoms in the diagnosis of depression in elderly male medical patients. Am J Psychiatry 1989; 146:1197–1200.
21. Emmons CA, Fetting JH, Zonderman AB. A comparison of the symptoms of medical and psychiatric patients matched on the Beck Depression Inventory. Gen Hosp Psychiatry 1987; 9:398–404.
22. Gardner WN. The pathophysiology of hyperventilation disorders. Chest 1996; 109: 516–534.
23. Lewis BI. The hyperventilation syndrome. Ann Intern Med 1953; 38:918–927.
24. Bass C, Gardner WN. Respiratory and psychiatric abnormalities in chronic symptomatic hyperventilation. Br Med J 1985; 290:1387–1390.
25. Lum C. The syndrome of habitual chronic hyperventilation Rec Adv Psychosom Med 1976; 3:196–229.
26. Lewis BI. Hyperventilation syndrome. California Med 1938; 91:121–127.
27. Gardner WN, Meah MS, Bass C. Controlled study of respiratory responses during prolonged measurement in patients with chronic hyperventilation. Lancet 1986; 2: 826–830.
28. Macefield G, Burke D. Paraesthesiae and tetany induced by voluntary hyperventilation increased human cutaneous and motor axons. Brain 1991; 114:527–540.
29. 2 breathing measured transcutaneously in humans by a bi-directional, pulsed ultrasound Doppler blood velocity meter. Acta Physiol Scand 1980; 110:167–173.
30. Foex P, Ryder WA, Bennett MJ. Carbon dioxide and coronary blood flow: direct effects of consequences of altered dynamics of the systemic circulation. Bull Eur Physiopathol Respir 1980; 16:185–194.
31. Margarian GJ. Hyperventilation syndromes: infrequently recognised common expressions of anxiety and stress. Medicine 1982; 61:219–236.
32. Bass C, Kartsounis L, Lelliott P. Hyperventilation and its relationship to anxiety and panic. Integrative Psychiatry 1987; 5:274–291.
33. Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL. Panic anxiety, dyspnea and respiratory disease. Am J Respir Crit Care Med 1996; 154:6–17.
34. Ley R. Agoraphobia, the panic attack and the hyperventilation syndrome. Behav Res Ther 1985; 23:79–81.
35. Anderson DJ, Noyes R Jr., Crowe RR. A comparison of panic disorder and generalised anxiety disorder. Am J Psychiatry 1984; 141:572–575.
36. Cowley DS, Roy-Byrne PP. Hyperventilation and panic disorder. Am J Med 1987; 83:929–936.
37. Bass C, Gardner W. Emotional influences on breathing and breathlessness. J Psychosom Res 1985; 29:599–609.
38. de Ruitter C, Garssen B, Rijken H, Kraaimaat F. The hyperventilation syndrome in panic disorder, agoraphobia and generalised anxiety disorder. Behav Res Ther 1989; 27:447–452.
39. Lum C. Hyperventilation syndromes in medicine and psychiatry: a review. J R Soc Med 1987; 80:229–231.
40. Carr RE, Lehrer PM, Hochron SM. Panic symptoms in asthma and panic disorder: a preliminary test of the dyspnea-fear theory. Behav Res Ther 1992; 30:251–261.
41. Gorman JM, Cohen BS, Liebowitz MR, Fyer AJ, Ross D, Davies SO, Klein DF. Blood gas changes and hypophosphatemia in lactate-induced panic. Arch Gen Psychiatry 1986; 45:31–39.
42. Papp LA, Martinez JM, Klein DF, Ross D, Liebowitz MR, Fyer AJ, Hollander E, Gorman JM. Arterial blood gas changes in panic disorder and lactate-induced panic. Psychiatry Res 1989; 28:171–180.
43. Gibbs DM. Hyperventilation-induced cerebral ischemia in panic disorder and effect of nimodipine. Am J Psychiatry 1992; 149:1589–1591.
44. Dager SR, Strauss WL, Marro KI, Richards TL, Metzger GD, Artru AA. Proton magnetic resonance spectrometry investigation of hyperventilation in panic and comparison subjects. Am J Psychiatry 1995; 152:666–672.
45. Maddock RJ, Carter CS. Hyperventilation-induced panic attacks in panic disorder with agoraphobia. Biol Psychiatry 1991; 29:843–854.
46. Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, Klein DF. Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984; 141:857–861.
47. 2 and hyperventilation in patient with panic disorder. Am J Psychiatry 1994; 151:547–553.
48. 2 on panic anxiety. Compr Psychiatry 1988; 29:490–497.
49. Asmundsen GJG, Stein MB. Vagal attenuation in panic disorder: an assessment of parasympathetic nervous system function and subjective reactivity to respiratory manipulations. Psychosom Med 1994; 56:187–193.
50. Holt PE, Andrews G. Hyperventilation and anxiety in panic disorder, social phobia, GAD and normal controls. Behav Res Ther 1989; 27:453–460.
51. Zandbergen J, van Aalst V, de Loof C, Pols H, Greiz E. No chronic hyperventilation in panic disorder patients. Psychiatry Res 1993; 47:1–6.
52. Hibbert G, Pilsbury D. Hyperventilation: is it a cause of panic attacks? Br J Psychiatry 1989; 155:805–809.
53. Gorman JM, Papp LA. Respiratory physiology of panic. In: Ballenger JC, ed. Neurology of Panic Disorder. New York: Alan R Liss, Inc. 1990:187–203.
54. Pitts FN, Jr., McClure JN. Lactate metabolism in anxiety neurosis. N Engl J Med 1967; 277:1329–1336.
55. Cowley DS, Arana GW. The diagnostic utility of lactate sensitivity in panic disorders. Arch Gen Psychiatry 1990; 47:277–284.
56. 2 challenge of patients with panic disorder Am J Psychiatry 1987; 144:1080–1082.
57. Gorman JM, Papp LA, Martinez J, Goetz RR, Hollender E, Liebowitz MR, Jordan F. High dose carbon dioxide challenge test in anxiety disorder patients. Biol Psychiatry 1990; 28:743–757.
58. 2, as a marker of panic in severe anxiety. Am J Psychiatry 1990; 147:796–797.
59. Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, Hollender E, Fyer AJ, Jorden F, Gorman JM. Diagnostic and substance specificity of carbon dioxideinduced panic. Am J Psychiatry 1993; 150:250–257.
60. Sanderson WC, Wetzler S. Five percent carbon dioxide challenge: valid analogue and marker of panic disorder. Biol Psychiatry 1990; 27:687–701.
61. Perna G, Battaglia M, Garberi A, Arancio C, Bertani A, Bellodi L. Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res 1994; 52:159–171.
62. 2 inhalation-provoked panic in a patient with panic disorder. J Clin Psychiatry 1986; 47:475–476.
63. Woods SW, Charney DS, Delgado PL, Heninger GR. The effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. J Clin Psychiatry 1990; 51:505–507.
64. 2-provoked panic in patients with panic disorder. Am J Psychiatry 1994; 151:1220–1222.
65. Perna G, Cocchi S, Bertani A, Arancio C, Bellodi L. Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind random, placebocontrolled study. J Clin Psychopharmacol 1994; 14:414–418.
66. Goetz RR, Klein DF, Gorman JM. Consistencies between recalled panic and lactateinduced panic. Anxiety 1994; 1:31–36.
67. McNally RJ, Hornig CD, Donnell CD. Clinical versus nonclinical panic: a test of suffocation false alarm theory. Behav Res Ther 1995; 33:127–131.
68. Woods SW, Charnley DS, Loke J, Goodman WK, Redmond DE Jr., Heninger GR. Carbon dioxide sensitivity in panic disorder. Arch Gen Psychiatry 1986; 43:900–909.
69. Pain MCF, Biddle M, Tiller JWG. Panic disorder, the ventilatory response to carbon dioxide and respiratory variables Psychosom Med 1988; 50:541–548.
70. Papp LA, Martinez JM, Klein DF, Coplan JD, Gorman JM. Rebreathing tests in panic disorder. Biol Psychiatry 1995; 38:240–245.
71. Elam M, Yao T, Thoren P, Svenssen TH. Hypercapnea and hypoxia: chemoreceptormediated control of locus coeruleus neurons and splanchnic nerves. Brain Res 1981; 222:373–381.
72. Klein DF. False suffocation alarms, spontaneous panics and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993; 50:306–317.
73. Papp LA, Klein DF, Gorman JM. Carbon dioxide hypersensitivity, hyperventilation and panic disorder. Am J Psychiatry 1993; 150:1149–1157.
74. Klein DF. Testing the suffocation false alarm theory of panic disorder. Anxiety 1994; 1:1–7.
75. Coplan JD, Sharma T, Rosenblum LA, Friedman S, Bassoff TB, Barbour RL, Gorman JM. Effects of sodium lactate infusion on cisternal lactate and carbon dioxide levels in non-human primates Am J Psychiatry 1992; 149:1369–1373.
76. Clark DM. A cognitive approach to panic. Behav Res Ther 1986; 24:461–470.
77. Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York: Guildford Press, 1988.
78. McNally RJ. Psychological approaches to panic disorder: a review. Psychol Bull 1990; 198:403–419.
79. Otto MW, Whittal ML. Cognitive-behavior therapy and the longitudinal course of panic disorder. Psychiatr Clin North Am 1995; 18:803–820.
80. Gaffney FA, Fenton BJ, Lane LD, Lake CR. Hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks Arch Gen Psychiatry 1988; 45:53–60.
81. Whittal ML, Goetsch VL. Physiological, subjective, and behavioral responses to hyperventilation in clinical and infrequent panic. Behav Res Ther 1995; 33:415–422.
82. Margraf J. Hyperventilation and panic disorder: a psychophysiological connection. Adv Behav Res Ther 1993; 15:49–74.
83. van der Molen GM, van den Hout MA Expectancy effects on respiration during lactate infusion. Psychosom Med 1988; 50:439–443.
84. Sanderson WC, Rapee RM, Barlow DH. The influence of an illusion of control on panic attacks induced via inhalation of 5.5% carbon dioxide-enriched air. Arch Gen Psychiatry 1989; 46:157–162.
85. Otto MW, Gould RA, Pollack MH. Cognitive-behavioral treatment of panic disorder: consideration for treatment of patients over the long term. Psychiatr Ann 1994; 24: 307–315.
86. Schweizer E, Winokur A, Rickels K. Insulin-induced hypoglycemia and panic attacks. Am J Psychiatry 1986; 143:654–655.
87. Pitts FN, Lactate and beta-agonists, beta-blockers, and anxiety. J Clin Psychiatry Monogr 1984; 2:25–39.
88. Roth WT, Margraf J, Ehlers A, Taylor CB, Maddock RJ, Davies S, Agras WS. Stress test reactivity in panic disorder. Arch Gen Psychiatry 1992; 49:301–310.
89. Clark TJH, Cochrane GM. Effect of personality on alveolar ventilation in patients with chronic airways obstruction. Br Med J 1970; 1:273–275.
90. Shershow JC, King A, Robinson S. Carbon dioxide sensitivity and personality. Psychosomatic Med 1973; 35:155–160.
91. Shershow JC, Kanarek JF, Kazemi H. Ventilatory response to carbon dioxide inhalation in patients with depression. Psychosomatic Med 1976; 38:282–287.
92. 2. Studies in neurotic psychiatric patients and practitioners of transcendental medication. Psychosomatic Med 1984; 46:347–362.
93. Damas-Mora J, Souster L, Jenner FA. Diminished hypercapnic drive in endogenous or severe depression. J Psychosomatic Res 1982; 26:237–245.
94. Littlefield C. Psychological treatment of patients with end-stage pulmonary disease. Monaldi Arch Chest Dis 1995; 50:58–61.
95. Yellowlees PM, Alpers JH, Bowden JJ, Bryant GD, Ruffin RE. Psychiatric morbidity in patients with chronic obstructive pulmonary disease. M J Aus 1987; 146:305–307.
96. Agle DP, Baum GL. Psychological aspects of chronic obstructive pulmonary disease. Med Clin North Am 1977; 61:749–758.
97. DeCencio DV, Leshner M, Leshner B. Personality characteristics of patients with chronic obstructive pulmonary emphysema. Arch Phys Med Rehab 1968; 49:471–475.
98. Covino NA, Dirks JF, Kinsmen RA, Seidal JA. Patterns of depression in chronic illness. Psychother Psychosom 1982; 37:144–153.
99. Foxall MJ, Ekberg JY, Griffith N. Comparative study of adjustment patterns of chronic obstructive pulmonary disease patients and peripheral vascular disease patients. Heart Lung 1987; 16:354–363.
100. Appleton WS. How depressed patients adversely affect their marriages. Med Aspects Human Sexuality 1982; 16:154–167.
101. Czajkowski SM, McSweeny AJ. The role of psychosocial factors in chronic obstructive pulmonary disease. Phys Med Rehab Clin North Am 1996; 7:341–352.
102. Sandhu HS. Psychosocial issues in chronic obstructive pulmonary disease. Clin Chest Med 1986; 7:629–642.
103. Jensen PS. Risk protective factors and supportive interventions in chronic airways obstruction. Arch Gen Psychiatry 1983; 40:1203–1207.
104. Labuhn KT. An analysis of self-reported depressed mood in chronic obstructive pulmonary disease. Dissentation Abstracts International 1984; 45:524B.
105. Barstow RE. Coping with emphysema. Nurs Clin North Am 1974; 9:137–145.
106. DeAraujo G, Van Arsdel PP, Holmes TH et al. Life change, coping ability and chronic intrinsic asthma. J Psychosom Res 1973; 17:359–363.
107. Patttison EM, Rhodes RJ, Dudley DL. Response to group treatment in patients with severe chronic lung disease Int J Group Psychother 1971; 21:214–255.
108. Dudley DL, Glaser EM, Jorgenson BM, et al. Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease, Part 1: Psychosocial and psychological considerations. Chest 1980; 77:413–420.
109. Burns BH, Howell JBL. Disproportionately severe breathlessness in chronic bronchitis. Q J Med 1969; 38:277–294.
110. Howell JBL. Behavioural breathlessness. Thorax 1990; 45:287–292.
111. Olesen M Subjectively perceived quality of life. Image: J Nursing Scholarship 1990; 22:187–190.
112. Diener E. Subjective well-being. Psychol Bull 1984; 95:542–575.
113. McSweeny AJ, Grant I, Heaton RK, Adams KM, Timms RM. Life quality of patients with chronic obstructive pulmonary disease. Arch Int Med 1982; 142:473–478.
114. Prigatano GP, Wright EC, Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease Arch Int Med 1984; 144: 1613–1619.
115. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787–805.
116. Moody L, McCormick K, Williams A. Disease and symptom severity, functional status and quality of life in chronic bronchitis and emphysema. J Behav Med 1990; 13:297–306.
117. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992; 145:1321–1327.
118. Anderson KL. The effect of chronic obstructive pulmonary disease on quality of life. Res Nurs Health 1995; 18:547–556.
119. Burckhardt CS, Woods SL, Schultz AA, Ziebarth DM. Quality of life of adults with chronic disease: a psychometric study. Res Nurs Health 1989; 12:347–354.
120. Guyatt GH, Townsend M, Berman LB, Pugsley SO. Quality of life in patients with chronic airflow limitation. Br J Dis Chest 1987; 81:45–54.
121. Rutter BM. The prognostic significance of psychological factors in the management of chronic bronchitis. Psychol Med 1979; 9:63–70.
122. Dudley DL, Glaser EM, Jorgenson BN, Logan DL. Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease: Part 2. Psychosocial treatment. Chest 1980; 77:544–551.
123. Agle DP, Baum GL, Chester EH et al. Multidisciplinary treatment of chronic pulmonary insufficiency. Psychological aspects of rehabilitation. Psychosomat Med 1973; 35:41–45.
124. Kass I, Dyksterhuis JE, Rubin H, Patil KD. Correlation of psychophysiologic variables with vocational rehabilitation outcome in patients with chronic obstructive pulmonary disease. Chest 1975; 67:433–440.
125. Lustig FM, Haas A, Castillo R. Clinical and rehabilitation regime in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 1972; 53:315–322.
126. Oswald NC, Waller RE, Drinkwater J. Relationship between breathlessness and anxiety in asthma and bronchitis: a comparative study. Br Med J 1970; 2:14–17.
127. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patient with COPD. Chest 1985; 87:35–38.
128. Beck AT, Ward CH, Mendleson M, Mock J, Erbough J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561–571.
129. Spielberger CD, Gorsuch RL, Lushene RE. STAI Manual. Palo Alto, CA: Consulting Psychologists Press, Inc., 1970.
130. Karajgi B, Rifkin A, Doddi S, Kolli R. The prevalence of anxiety disorders in patients with COPD. Am J Psychiatry 1990; 147:200–201.
131. Robins NL, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949–958.
132. Harte R, Karvounis S, Eiser NM, Isaac M. Prevalence of psychiatric disorders in a hospital based COPD clinic. Am J Respir Crit Care Med 1997; 155:A718.
133. Diagnostic and Statistical Manual of Mental Disorders 111R. Washington DC: American Psychiatric Association, 1987.
134. Borak J, Chodosowska E, Matuszewski A, Zielinski J. Emotional status does not alter exercise tolerance in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12:370–373.
135. Grant I, Heaton RK, McSweeny AJ. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1982; 142:1470–1476.
136. Mishima M, Oku Y, Muro S, Hirai T, Chin K, Ohi M, Nakagawa M, Fujita M et al. Relationship between dyspnea in daily life and psycho-physiologic state in patients with chronic obstructive pulmonary disease during long-term domiciliary oxygen therapy. Int Med 1996; 35:453–458.
137. Janssen J-P, Rochat T, Frey J-G, Dousse N, Pichard C, Tschopp J-M. Health-related quality of life in patients under long-term oxygen therapy: a home-based descriptive study. Respir Med 1997; 91:592–602.
138. Lahdensuo A, Ojanen M, Ahonen A, Laitinen J, Poppius H, Salorinne Y, et al. Psychological effects of continuous oxygen therapy in hypoxaemic chronic obstructive pulmonary disease patients. Eur Respir J 1989; 2:977–980.
139. Borak J, Sliwinski P, Piasecki Z, Zielinski J. Psychological status of COPD patients on long term oxygen therapy. Eur Respir J 1991; 4:59–62.
140. Geddes DM, Rudolf M, Saunders KB. Effect of niatrazepam and flurazepam on the ventilatory response to carbon diaoxide. Thorax 1976; 31:548–551.
141. Mitchell-Heggs P, Murphy K, Minty K, et al. Diazepam in the treatment of dyspnoea in the ‘pink puffer’ syndrome. Q J Med 1980; 49:9–20.
142. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J 1981; 283:343–346.
143. Johnson MA, Woodcock AA, Dehahu M, Geddes DM. Are pink puffers more breathless than blue bloaters? Br Med J 1983; 286:179–183.
144. Rappaport D, Greenberg H, Goldring R. Differing effects of the anxiolytic agent buspirone and diozepram on control of breathing. Clin Pharmacol Ther 1991; 49:394.
145. Roo S, Sherbaniak RW, Prosad K, Lee SJK, Sproule B. Cardiopulmonary effects of diazepam. Clin Pharmacol Ther 1972; 14:182–189.
146. Eimer M, Cable T, Gal P, et al. Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract 1985; 21:359–362.
147. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90:832–836.
148. Scuvee-Moreau J, Giesbets J, Dresse A. Electrophysiological and microiontophoretic studies with buspirone: Influence on the firing rate of central monoaminergic neurosins and their responsiveness to dopamine, clonidine or GABA. Arch Int Physiol Biochim 1987; 95:439–446.
149. Saughter MK, McMillan BA, German DC. Buspirone, a non-benzodiazepine anxiolytic increases locus coeruleus noradrenergic neuronal activity. Fut J Pharmacol 1983; 86:107–110.
150. Garner SJ, Eldridge FL, Wagner PG, et al. Buspirone: an anxiolytic drug that stimulates respiration. Am Rev Respir Dis 1989; 139:946–950.
151. Mendelson WB, Martin JV, Rappaport DM. Effects of buspirone on sleep and respiration Am Rev Respir Dis 1990; 141:1527–1530.
152. Craven J, Sutherland A. Buspirone for anxiety disorders in patients with severe lung disease. Lancet 1991; 338:249.
153. Alderman C, Frith P, Ben-Tovim D. Buspirone for the treatment of anxiety in patients with chronic obstructive pulmonary disease. J Clin Psychopharmacol 1996; 16:410–411.
154. Singh NP, Despars JA, Stansbury DW, Avalos K, Light RW. Effects of buspirone on anxiety levels and exercise tolerance in patients with mild chronic obstructive pulmonary disease. Chest 1993; 103:800–804.
155. Argyropoulou P, Patakas D, Vasiliadis P, Georgopoulos D. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60:216–220.
156. Series F, Cormier Y, La Forge J. Changes in day and night time oxygenation with protryptyline in patients with chronic obstructive pulmonary disease. Thorax 1989; 44:275–279.
157. Series F, Cormier Y. Effects of protryptyline on diurnal and nocturnal oxygenation in patients with chronic obstructive pulmonary disease. Ann Intern Med 1990; 113:507–511.
158. Series F, Marc I, Cormier Y, La Forge J. Long-term effects of protriptyline in patients with chronic obstructive pulmonary disease. Am Rev Repir Dis 1993; 147:1487–1493.
159. Strom K, Boman G, Pehrsson K, Alton M, Singer J, Rydstrom P-O et al. Effect of protriptyline, 10mg daily on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J 1995; 8:425–429.
160. Gordon GH, Michiels TM, Mahutte CK, Light RW. Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease. Psychiatry Res 1985; 15:25–32.
161. Light RW, Merill EJ, Despars J, Gordon GH, Mutalipassi LR. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med 1986; 146:1377–1380.
162. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, Van Tuien C. Improvement in mood, physical symptoms and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190–201.
163. Deyo RA, Inui TS. Towards clinical applications of health status measures: sensitivity of scales to clinically important changes. Health Serv Res 1984; 19:275–289.
164. Mueller R, Lundberg D, Breese G, et al. The neuropharmacology of respiratory control. Pharmacol 1982; 84:255–285.
165. Lundberg D, Mueller R, Breese G. An evaluation of the mechanism by which serotoninergic activation depresses respiration. J Pharmacol Exp Ther 1980; 212:397–404.
166. Matthews AW. The relationship between central carbon dioxide sensitivity and clinical features in patients with chronic airways obstruction. Q J Med 1977; 46:179–195.
167. Papp LA, Weiss JR, Greenberg HE, et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders (letter) Am J Psychiatry 1995; 152: 1531.
168. Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998; 39:24–29.
169. Eiser N, Harte R, Karvounis S, Phillips C, Isaac M. Effect of treatment of depression in patients with COPD. Am J Respir Crit Care Med 1998; 157:A785.
170. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389.
171. Dudley D, Martin C, Holmes T. Dyspnoea, psychologic and physiologic observations. J Psychosom Res 1968; 12:205–214.
172. Agle DP, Baum GL, Chester EH, Wendt M. Multidiscipline treatment of chronic pulmonary insufficiency. Psychosom Med 1973; 35:41–49.
173. Blake RL Jr., Vandiver TA, Braun S, et al. A randomized controlled evaluation of psychosocial intervention in adults with chronic lung disease. Fam Med 1990; 22:365–370.
174. Rosser R, Guz A. Psychological approaches to breathlessness and its treatment. J Psychosom Res 1981; 25:439–447.
175. Eiser NM, Evans S, Jeffers A, West C. Effects of psychotherapy on dyspnoea in moderately severe COPD: a pilot study. Eur Respir J 1997; 10:1581–1584.
176. Carrieri-Kohlman V, Douglas MK, Gormley JM et al. Desensitization and guided mastery. Treatment approaches for the management of dyspnea Heart Lung 1993; 22:226–234.
177. Douglas MK, Carrieri-Kohlman V, Gormley JM, et al Differentiation among components of dyspnea in exercising patients with COPD. Am Rev Respir Dis 1992; 145: A766.
178. Wilson RC, Jones PW. Differentiation between the intensity of breathlessness and the distress it evokes in normal subjects during exercise. Clin Sci 1991; 80:65–70.
179. Belman MJ, Brooks LR, Ross DJ, et al. Variability of breathlessness measurement in patients with chronic obstructive pulmonary disease. Chest 1991; 99:566–571.
180. Carrieri-Kohlman V, Douglas MK, Gormley JM, et al. Exercise may result in greater decreases in anxiety and distress associated with dyspnea than in dyspnea intensity or perceived work of breathing. Am Rev Respir Dis 1992; 145:A765.
181. Gormley JM, Carrieri-Kohlman V, Douglas M, Stulbarg MS. Patients with COPD increase their self-efficacy and performance during an exercise program. Am Rev Respir Dis 1992; 145:A477.
182. Gift AG, Moore T, Soeken K. Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs Res 1992; 41:241–246.
183. Thompson SC. Will it hurt less if I can control it? Psychol Bull 1981; 90:89–101.
184. Kaplan RM, Atkins CJ, Reinsch S. Specific efficacy, expectations mediate exercise compliance in patients with COPD. Health Psychol 1984; 3:223–242.
185. Toshima MT, Kaplan RM, Reis AL. Specific efficacy expectations in chronic obstructive pulmonary disease In: Schwartzer R, ed. Self-Efficacy: Thought Control of Action. Washington, D.C.: Hemisphere, 1992.
186. Kaplan RM, Reis AL, Prewitt LM, et al. Self-efficacy expectations predict survival for patients with chronic obstructive pulmonary disease. Health Psychol 1994; 13:366–368.
187. Gayle RC, Spitler DL, Karper WB, Jaeger RM, Rice SN. Psychological changes in exercising COPD patients. Int J Rehab Res 1988; 11:335–342.
188. Dekhuijzen PNR, Beek MML, Folgering HTM, van Herwaarden CLA. Psychological changes during pulmonary rehabilitation and target-flow inspiratory muscle training in COPD patients with a ventilatory limitation to exercise. Int J Rehab Res 1990; 13: 109–117.
189. Renfroe KL. Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 1988; 17:408–413.
190. Sassi-Dambron DE, Eakin EG, Ries AL, Kaplan RM. Treatment of dyspnea in COPD: a controlled clinical trial of dyspnea management strategies. Chest 1995; 107:724–729.
191. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Int Med 1995; 122:823–832.
192. Toshima MT, Kaplan RM, Reis AL. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: Short-term effects on exercise endurance and health status. Health Psychol 1990; 9:237–252.
193. Ries AL for ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation Joint ACCP/AACVPR evidence-based guidelines. Chest 1997; 112: 1363–1396.
194. Fishman DB, Petty TL. Physical, symptomatic and psychological improvement in patients receiving comprehensive care for chronic airway obstruction. J Chronic Dis 1971; 24:775–785.
195. Emery CF, Leatherman NE, Burker EJ, et al. Psychological outcomes of a pulmonary rehabilitation program. Chest 1991; 100:613–617.
196. Ojanen M, Lahdensuo A, Laitinen J, et al. Psychosocial changes in patients participating in a chronic obstructive pulmonary disease rehabilitation program. Respiration 1993; 60:96–102.
197. Atkins BJ, Kaplan RM, Timms RM, Reinsch S, Zofback K. Behavioral exercise programs in the management of chronic obstructive pulmonary disease. J Consult Clin Psychol 1984; 52:591–603.
198. Carrieri-Kohlman V. Education, coaching and patient identified strategies. Symposium on treatments for the relief of dyspnea. Presented at the American Thoracic Society International Conference, Miami, 1992.
199. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773–778.